reversed-phase chromatography raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2025-09-22. Anything still debated is marked as such rather than presented as settled.
Full-length thymosin beta-4 consists of roughly forty-three amino acids and ranks among the more abundant small proteins in the cytoplasm. The fragment is much shorter, so it cannot reproduce every function attributed to the intact molecule. In cell culture, short actin-binding motifs can interfere with filament dynamics and cell movement, but such observations come from controlled experiments rather than from whole-animal work. Whether a truncated fragment produces the same effects as the parent protein remains an open question.
Interest in the peptide grew during the 2000s and 2010s, when studies of tendon and ligament injuries in horses reported changes in lesion size after treatment. Those reports circulated widely outside the scientific literature and shaped much of the current online discussion. Subsequent reviews noted inconsistent study design, small groups, and a shortage of independent replication. Popular descriptions often blur the line between the fragment, the complete protein, and unrelated growth factors, which complicates comparisons across sources.
TB-500 is a catalogue name applied to a synthetic peptide related to thymosin beta-4, an actin-binding protein found in most mammalian cells. Suppliers do not use the label consistently: some describe it as the full 43-residue protein, others as a short fragment from the actin-binding region, and others as a related tetrapeptide. Because the name is commercial rather than chemical, two products sold under it may not contain the same molecule. This naming ambiguity is the first point to check in any description of the material.
The most frequently cited identity is a seven-residue fragment with the sequence LKKTETQ, taken from the actin-binding domain of the parent protein. A separate molecule, N-acetyl-seryl-aspartyl-lysyl-proline, often shortened to Ac-SDKP, derives from the same protein's N-terminal region and appears in overlapping literature. Reported molecular masses therefore differ between sources, and a mass value on its own does not establish which fragment is present. Confirmation requires a defined sequence rather than a single number.
Research interest in thymosin beta-4 fragments centres on actin sequestration, cell migration and tissue repair models. Most published work uses cultured cells or animal wound and cardiac preparations, and findings are generally described as preliminary. No fragment of this protein has been approved as a therapeutic product by major regulators. Reviews of the field note inconsistent dosing, delivery routes and outcome measures across studies, which complicates direct comparison. The material is best understood as a laboratory reagent with an active but unresolved research literature.
| Property | Value | Notes |
|---|---|---|
| Generic designation | Synthetic thymosin beta-4 N-terminal fragment | Peptide nomenclature varies by supplier |
| Peptide length | Approximately 17 amino acid residues | Reported length sometimes differs between sources |
| N-terminal modification | Acetyl group | Affects mass and chromatographic behaviour |
| Compound class | Small synthetic peptide | Not a small-molecule drug |
| Common synonyms | TB4 fragment; thymosin beta-4 fragment | Naming is inconsistent in popular media |
Peptide bonds are susceptible to hydrolysis under extreme pH and to enzymatic cleavage if proteases are present. Heat, oxidising agents, and prolonged exposure to light also contribute to loss of material. Aggregation can occur at high concentrations or in certain buffer systems, and it may not be visible to the eye. Storage at -20 C or below is typical for both powder and aliquoted solutions, and desiccation of the powder is preferred.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography together with mass spectrometry. The chromatogram provides a purity estimate as a percentage of total peak area, while the mass spectrum confirms that the observed mass matches the expected value. Amino acid analysis or tandem mass spectrometry sequencing can provide additional confirmation. Reported purity figures depend on the column, gradient, and detection wavelength, so values from different laboratories are not directly comparable without method details.
Lyophilised peptide is normally reconstituted with sterile water or a neutral buffer shortly before use. Because repeated freeze-thaw cycles can degrade the material, dividing a reconstituted solution into single-use aliquots is a common practice. Working solutions are usually kept cold and protected from light. The exact shelf life depends on concentration, buffer composition, and handling, so it is often determined empirically rather than assumed.
TB-500 is a laboratory label applied to a short synthetic peptide that is widely described as a fragment of thymosin beta-4, an actin-binding protein present in most mammalian cells. Suppliers and review articles usually present TB-500 as the N-terminal region of that protein, but the exact sequence attached to the name is not consistent across sources. Some product descriptions list a seven-residue chain; others use the label loosely for the parent protein itself. Because of that variation, any technical discussion of TB-500 needs to state which sequence is meant.
Thymosin beta-4 contains 43 amino acids and has a reported molecular mass near 4963 Da. The short fragment most often associated with the TB-500 label, an acetylated chain beginning LKKTETQ, has a reported mass near 889 Da, so the two are easily separated in analytical work. Mass spectrometry and amino acid analysis can confirm which material is present in a given sample. Statements treating TB-500 and thymosin beta-4 as interchangeable are therefore imprecise, even though the two appear together in much of the same literature.
Interest in the compound comes largely from studies of the parent protein, which participates in actin sequestration, cell migration and tissue repair processes. Whether a short fragment reproduces those activities is a separate question that remains open in the published record. Many summaries describe mechanisms by analogy to thymosin beta-4 rather than from direct measurements on the fragment. Claims about activity should be treated as provisional unless a cited study specifies the exact peptide, its purity and the assay used.
Their global dissemination is driven in part by horizontal gene transfer on plasmids and has been associated with selection pressure from colistin use, particularly in food-producing animals. Mobile colistin resistance genes also occur in settings without local agricultural colistin use. A 2026 genomic study from New Zealand, where colistin has never been licensed for use in food-producing animals, characterized 71 mcr-positive clinical isolates and compared them with 1,543 mcr-carrying plasmids sampled from 60 countries and regions between 1984 and 2024. The analysis resolved 14 major plasmid lineages associated with different mcr variants and found frequent co-carriage of other antimicrobial-resistance genes, indicating that transmissible plasmid backbones and co-selection by other resistance determinants can contribute to the persistence and dissemination of mcr genes even where direct colistin selection pressure is limited. The emergence of the mcr-9 gene is quite remarkable. Use of colistin to treat Acinetobacter baumannii infections has led to the development of resistant bacterial strains. They have also developed resistance to the antimicrobial compounds LL-37 and lysozyme, produced by the human immune system. This cross-resistance is caused by gain-of-function mutations to the pmrB gene, which controls the expression of lipid A phosphoethanolamine transferases (similar to mcr-1) located on the bacterial chromosome. Similar results have been obtained with mcr-1 positive E.
=== Schwentner et al. (2017) === In a 2017 molecular study, Schwentner et al. proposed a new taxon Labiocarida (derived from "labium" [Latin: lip] and "carida" [Greek: prawn]) for the clade comprising Hexapoda and Remipedia based on the presence of the functional labium in both taxa, which is consistent with other studies. The study also supports a group including Copepoda and Malacostraca in Multicrustacea.
Prolyl hydroxylase is a tetramer with 2 unique subunits. The α subunit is 59 kDa and is responsible for both peptide binding and for catalytic activity. The peptide binding domain spans residues 140-215 of the α subunit, and consists of a concave surface lined with multiple tyrosine residues which interact favorably with the proline-rich substrate. The active site consists of Fe2+ bound to two histidine residues and one aspartate residue, a characteristic shared by most 2-oxoglutarate-dependent dioxygenases. The 55 kDa β subunit is responsible for the enzyme’s localization to and retention in the endoplasmic reticulum. This subunit is identical to the enzyme known as protein disulfide isomerase.
Sources: en.wikipedia.org
In the early nineteenth century, it was still undecided which port would be chosen as the primary sea link along the route from London to Dublin: Porthdinllaen, on the Llŷn Peninsula, or Holyhead in Anglesey. In May 1806, the Porthdinlleyn Harbour Act 1806 (46 Geo. 3. c. xxxiv) approved new buildings in Porthdinllaen when it seemed that the town would be chosen. Porthdinllaen was almost as far west as Holyhead, but Holyhead was more accessible because of Thomas Telford's road developments. Porthdinllaen Harbour Company was formed in 1808 in preparation, but the bill before Parliament to constitute Porthdinllaen as a harbour for Irish trade was rejected in 1810. Holyhead's maritime importance was at its height in the 19th century with a 1+3⁄4-mile-long (2.8-kilometre) sea breakwater. Holyhead Breakwater, built to create a safe harbour for vessels caught in stormy waters on their way to Liverpool and the industrial ports of Lancashire; it is the longest breakwater in the UK. Throughout the later 18th century and the entire 19th century, Holyhead was a crucial transit point for landed gentry and British parliamentarians and military officials who were travelling from Ireland to London. It was also a transit point for British owners of multinational estates visiting their 'other lands' or London houses. The port of Holyhead saw significant development throughout the 19th century to accommodate the growing passenger traffic between Holyhead and Dublin, which reached approximately 14,000 passengers annually by 1814.
=== Catalyst === In 2014, researchers at the University of Western Australia discovered nano sized fragments of graphene can speed up the rate of chemical reactions. In 2015, researchers announced an atomic scale catalyst made of graphene doped with nitrogen and augmented with small amounts of cobalt whose onset voltage was comparable to platinum catalysts. In 2016 iron-nitrogen complexes embedded in graphene were reported as another form of catalyst. The new material was claimed to approach the efficiency of platinum catalysts. The approach eliminated the need for less efficient iron nanoparticles.
Aesthetic Theory (1970) The Stars Down to Earth and Other Essays on the Irrational in Culture (1975) Beethoven: The Philosophy of Music; Fragments and Texts (1993) The Psychological Technique of Martin Luther Thomas' Radio Addresses (2000) Kant's 'Critique of Pure Reason' (2002) Current of Music (2006) Aspects of the New Right-Wing Extremism (1969 lecture; first published in English, 2020)
Probucol was originally designed as an antioxidant polymer stabilizer for rubber tires. It was later found to reduce LDL-C levels independently of the LDL receptor and became a prescription drug. Its approval predated statins by a decade.
Sources: en.wikipedia.org
=== Mitral regurgitation === Chest x-ray in mitral regurgitation can show an enlarged left atrium, as well as pulmonary venous congestion. It may also show valvular calcifications specifically in combined mitral regurgitation and stenosis due to rheumatic heart disease. ECG typically shows left atrial enlargement, but can also show right atrial enlargement if the disease is severe enough to cause pulmonary hypertension. Echocardiography is useful in visualizing the regurgitant flow and calculating the RF. It can also be used to determine the degree of calcification, and the function and closure of the valve leaflets. Severe disease has an RF of >50%, while progressive mitral regurgitation has an RF of <50%.
== History == Bio-Rad Laboratories was founded in 1952 by David Schwartz and his wife Alice, both recent graduates of the University of California, Berkeley. In 1976, Bio-Rad acquired Environmental Chemical Specialties (ECS), a producer of human control serum. In 2008, Bio-Rad were notable for being the opening bell ringers at the New York Stock Exchange on 24 October, a date which went down in financial history as 'Bloody Friday', which saw many of the world's stock exchanges experience the worst declines in their history, with drops of around 10% in most indices. In 2011, Bio-Rad acquired a new technology, droplet digital PCR. Droplet digital PCR allows scientists to distinguish rare sequences in tumors and precisely measure copy number variation. In January 2013, Bio-Rad purchased AbD Serotec, a division of MorphoSys AG. This added Serotec's more than 15,000 antibodies, kits, and accessories to Bio-Rad's portfolio of research and clinical diagnostic products. In 2016, the company had direct distribution channels in over 35 countries outside the United States through subsidiaries whose focus is sales, customer service and product distribution. In some locations outside and inside these 35 countries, sales efforts were supplemented by distributors and agents. In 2017, Bio-Rad acquired RainDance Technologies, a droplet-based PCR systems manufacturer. In March 2021, Bio-Rad announced a partnership with Roche.
=== Classification === The term complex carbohydrate was first used in the U.S. Senate Select Committee on Nutrition and Human Needs publication Dietary Goals for the United States (1977) where it was intended to distinguish sugars from other carbohydrates (which were perceived to be nutritionally superior). However, the report put "fruit, vegetables and whole-grains" in the complex carbohydrate column, despite the fact that these may contain sugars as well as polysaccharides. The standard usage, however, is to classify carbohydrates chemically: simple if they are sugars (monosaccharides and disaccharides) and complex if they are polysaccharides (or oligosaccharides). Carbohydrates are sometimes divided into "available carbohydrates", which are absorbed in the small intestine and "unavailable carbohydrates", which pass to the large intestine, where they are subject to fermentation by the gastrointestinal microbiota.
Sources: en.wikipedia.org
It is a synthetic peptide based on a short sequence near the start of thymosin beta-4. It is supplied as a research chemical rather than as a licensed pharmaceutical product.
No. Thymosin beta-4 is the full-length protein of about forty-three amino acids, while the fragment covers only its beginning. The two are related but are not interchangeable in experimental or analytical terms.
The label is a catalogue designation that became common in non-technical discussion. Scientific papers usually refer to the fragment by sequence or as a thymosin beta-4 N-terminal peptide.
TB-500 is a trade-style label for a synthetic peptide connected to thymosin beta-4. It is sold mainly through research-chemical channels and is not a single chemically defined product across suppliers.